Cordis, which was acquired by H&F in August 2021, is to make an initial $35 million investment and provide an upfront payment of $200 million at closing in 2023. Achieving regulatory milestones will trigger a $125 million payment and commercial achievements through to 2029 are tied to an additional $775 million.
Cordis, which formerly owned by Johnson & Johnson, is now backed by backed by H&F and global investment firm KKR as well as Ajax Health.
Switzerland-headquartered Medalliance is the developer of the Selution Sustained Limus Release (SLR) sirolimus-eluting balloon, which Cordxis believes fits well with its existing product line.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.